Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

BACKGROUND: Fludarabine, cyclophosphamide, rituximab (FCR) can provide prolonged disease-free survival for younger, fit patients with chronic lymphocytic leukaemia (CLL) with mutated IGHV; however, patients with unmutated IGHV rarely have durable responses. Ibrutinib is highly effective for patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Davids, Matthew S, Brander, Danielle M, Kim, Haesook T, Tyekucheva, Svitlana, Bsat, Jad, Savell, Alexandra, Hellman, Jeffrey M, Bazemore, Josie, Francoeur, Karen, Alencar, Alvaro, Shune, Leyla, Omaira, Mohammad, Jacobson, Caron A, Armand, Philippe, Ng, Samuel, Crombie, Jennifer, LaCasce, Ann S, Arnason, Jon, Hochberg, Ephraim P, Takvorian, Ronald W, Abramson, Jeremy S, Fisher, David C, Brown, Jennifer R
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7036668/
https://ncbi.nlm.nih.gov/pubmed/31208944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(19)30104-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados